New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts
about
RhoT1 and Smad4 are correlated with lymph node metastasis and overall survival in pancreatic cancerThe complexities of epidemiology and prevention of gastrointestinal cancersEpigenetics and pancreatic cancer: pathophysiology and novel treatment aspectsAssociation study of type 2 diabetes genetic susceptibility variants and risk of pancreatic cancer: an analysis of PanScan-I data.Pancreatic cancer organotypics: High throughput, preclinical models for pharmacological agent evaluationPancreatic cancer susceptibility loci and their role in survival.Breaking the NF-κB and STAT3 alliance inhibits inflammation and pancreatic tumorigenesis.Diabetes and pancreatic cancer.Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cellsTherapeutic effect of human iPS-cell-derived myeloid cells expressing IFN-β against peritoneally disseminated cancer in xenograft models.Prognostic value of circulating tumor cells in patients with pancreatic cancer: a meta-analysis.Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations.Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens.MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenograftsHypoxia promotes C-X-C chemokine receptor type 4 expression through microRNA-150 in pancreatic cancer cells.Pancreatic cancer: chemotherapy and radiotherapy.Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation.Analysis of whole genomic expression profiles and screening of the key signaling pathways associated with pancreatic cancerPharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancerAberrant glycogen synthase kinase 3β in the development of pancreatic cancer.Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium.Metabolic disorder, inflammation, and deregulated molecular pathways converging in pancreatic cancer development: implications for new therapeutic strategies.Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling.Pancreatic cancer in 2010: new insights for early intervention and detection.Diabetes, gestational diabetes and the risk of cancer in women: epidemiologic evidence and possible biologic mechanisms.ATRA modulates mechanical activation of TGF-β by pancreatic stellate cells.Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.Gestational diabetes and risk of incident primary cancer: a large historical cohort study in Israel.
P2860
Q21134105-64DDC78E-F609-4E9D-8B9A-0C241792B73EQ26865429-392365B4-2E93-4A6D-83C9-EC23E5D6F74AQ33801377-11B1839F-FA31-40E7-8B76-B074BA783CADQ33857217-6AE780F8-E0A1-45A1-B89F-736B4046AEA1Q33886981-DA429E16-31E8-486F-A1D1-D90BD2D6FADBQ34085823-3DBF0EF3-0FCF-4977-A723-11F34F5EE15DQ34332547-96EA60AC-119E-404C-9E3C-B2899AE5B71FQ34634263-182E3370-2E36-4C85-877C-313E9F42CADBQ34714647-81920172-A0D4-46EE-9FD3-8E48A503FC0EQ34797365-F00797CB-7B29-4B9C-8760-F4750BB57FB2Q35039154-32448041-3BB9-4463-BE13-DAC8B6FCF954Q35104958-F93FE0B7-076B-4854-AE76-2C5B434FE530Q35797487-18CCF501-DD69-4219-8602-6960F19EBB4DQ35839058-7E4D1753-EED7-4C82-BF3F-ABDEEE7D4284Q35870123-68C4903D-7D39-4009-B756-026F51FB885CQ35913523-2C606734-D341-4BFE-940D-4D14E57F1CE5Q35954892-10E512F8-1CDB-49C9-9E5A-66E294367473Q36196775-375A88F0-F1A6-4AFB-A095-CB056DF5AB3EQ36351453-D5B23DBC-E99E-4F7C-922B-0FCECC72D647Q36450022-A7E8D71B-F323-4FE9-9606-2CE1548FD52EQ36487491-249B24A1-5931-4826-95BA-20F5D1C053EBQ37129787-DE0EB24C-F3C1-420E-8134-F9DF5E97E830Q37474343-EAE5552F-B757-49A3-BB28-2DC90081C01CQ37835701-884CD60A-FAF4-41EC-BB72-978BDB272C71Q37853559-22A34B67-0872-4A00-9FD7-93B904725925Q42125567-7D221155-532F-4F2A-B54F-58756E48B7A8Q44299542-3AC37998-B593-448A-8EFD-815B08B3E99CQ44737786-4D38496A-BC96-40CD-8FA8-DBD1E723FC06
P2860
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts
description
2010 nî lūn-bûn
@nan
2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts
@ast
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts
@en
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts
@nl
type
label
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts
@ast
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts
@en
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts
@nl
prefLabel
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts
@ast
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts
@en
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts
@nl
P2860
P1476
New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts
@en
P2093
Donghui Li
James L Abbruzzese
P2860
P304
P356
10.1158/1078-0432.CCR-09-1942
P407
P577
2010-07-20T00:00:00Z